May 4, 2013
-- Reports Corner has added a new report "ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!". Please visit the link https://www.reportscorner.com/
Gilead entered the HCV race with the acquisition of Pharmasset in 2011 and ABBV through its alliance with Enanta (ENTA) in 2006. Gilead’
s Sofosbuvir (PhIII, PMI) in combination with RBV and GS-5885 (PhIII, NS5A inhibitor) is all set to enter the market by 2014 but ENTA/ABBV’s DAAs (ABT-450, PI/r + ABT-333, PMI + ABT-267, NS5AI) will not be too far behind. In PhIIb AVIATOR study, tirade of DAAs demonstrated SVR12 (ITT) of 97.5%, and 93.3% in treatment-naï
ve pts and null responder HCV GT1 pts respectively. The total INF-free HCV market is expected to grow beyond $10b and as a second entrant ABT-450 combo could achieve…..For more detail, please read our initiation report released on 17th April, 2013 on ENTA titled “Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!